Kyongbo Pharmaceutical Co., Ltd (KRX:214390)

South Korea flag South Korea · Delayed Price · Currency is KRW
5,210.00
-520.00 (-9.08%)
Mar 4, 2026, 3:30 PM KST
-19.22%
Market Cap 136.99B
Revenue (ttm) 252.20B
Net Income (ttm) 2.37B
Shares Out 23.91M
EPS (ttm) 98.86
PE Ratio 57.96
Forward PE n/a
Dividend 50.00 (0.83%)
Ex-Dividend Date Dec 29, 2025
Volume 133,078
Average Volume 62,927
Open 5,680.00
Previous Close 5,730.00
Day's Range 5,150.00 - 5,680.00
52-Week Range 4,755.00 - 6,750.00
Beta 0.84
RSI 31.33
Earnings Date n/a

About Kyongbo Pharmaceutical

Kyongbo Pharmaceutical Co., Ltd manufactures and sells active pharmaceutical ingredients and finished drugs in South Korea and internationally. The company offers general, cephalosporins, and anti-cancer APIs; prescription drugs, including anesthetic, cardiovascular, digestive, and antibiotics; and OTC drugs. It also provides medical devices, including portable X-ray machine and ultrasonic diagnostic equipment; and extraporeal shockwave therapy and temperature control PROBE. In addition, the company is involved in CDMO business; and research an... [Read more]

Sector Healthcare
Founded 1987
Country South Korea
Stock Exchange Korea Stock Exchange
Ticker Symbol 214390
Full Company Profile

Financial Performance

In 2024, Kyongbo Pharmaceutical's revenue was 238.56 billion, an increase of 10.26% compared to the previous year's 216.36 billion. Earnings were 4.64 billion, an increase of 55.98%.

Financial Statements

News

There is no news available yet.